Statements (36)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
gptkb:Biotest_AG
Dova Pharmaceuticals Swedish Orphan Biovitrum AB |
| gptkbp:ceo |
Johan Luthman
|
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:focus |
rare diseases
|
| gptkbp:founded |
gptkb:2001
|
| gptkbp:headquarters |
gptkb:Stockholm,_Sweden
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sobi AB
|
| gptkbp:market |
gptkb:Europe
gptkb:Asia gptkb:North_America |
| gptkbp:number_of_employees |
approximately 1,000
|
| gptkbp:partnership |
gptkb:Takeda_Pharmaceutical_Company
gptkb:Astra_Zeneca gptkb:Sanofi gptkb:Boehringer_Ingelheim gptkb:Bristol-Myers_Squibb gptkb:Pfizer gptkb:Roche |
| gptkbp:product |
gptkb:Alprolix
gptkb:Kineret gptkb:Takhzyro Eloctate Gamifant |
| gptkbp:research_areas |
hematology
immunology |
| gptkbp:revenue |
1.5 billion SEK (2020)
|
| gptkbp:subsidiary |
Sobi Gmb H
Sobi UK Ltd. Sobi USA, Inc. |
| gptkbp:traded_on |
gptkb:Nasdaq_Stockholm
|
| gptkbp:website |
www.sobi.com
|
| gptkbp:bfsParent |
gptkb:Biogen_Idec_MA_Inc.
|
| gptkbp:bfsLayer |
6
|